Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Dancey

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Hematology. American Society of Hematology. Education Program|November 26, 2002
Update on epidemiology and therapeutics for non-Hodgkin's lymphomaJulie M Vose, Brian C-H Chiu, Bruce D Cheson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumorsMartin J Edelman, Kenneth S Bauer, Suhlan Wu, et al.
Investigational New Drugs|September 8, 2006
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinomaMinaxi Jhawer, Lee Rosen, Janet Dancey, et al.
Breast Cancer Research and Treatment|July 11, 2006
Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19Jianhua Liu, Dongsheng Tu, Janet Dancey, et al.
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
New targets for cancer chemotherapyAnthony J Murgo, Janet Dancey, S Gail Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Lori E Dodd, Edward L Korn, Boris Freidlin, et al.
Gynecologic Oncology|August 14, 2013
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancerRachel A Goodwin, Rahima Jamal, Dongsheng Tu, et al.
Cancer|July 12, 2007
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinomaMelanie B Thomas, Romil Chadha, Katrina Glover, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2024
Correlative Science in the Cooperative Group System: Re-Engineering for SuccessPeter J O'Dwyer, Norman Wolmark, Douglas S Hawkins, et al.
Cancer Biology & Therapy|June 9, 2006
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancerAthanassios Argiris, Ezra Cohen, Theodore Karrison, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Hematology. American Society of Hematology. Education Program|November 26, 2002
Update on epidemiology and therapeutics for non-Hodgkin's lymphomaJulie M Vose, Brian C-H Chiu, Bruce D Cheson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumorsMartin J Edelman, Kenneth S Bauer, Suhlan Wu, et al.
Investigational New Drugs|September 8, 2006
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinomaMinaxi Jhawer, Lee Rosen, Janet Dancey, et al.
Breast Cancer Research and Treatment|July 11, 2006
Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19Jianhua Liu, Dongsheng Tu, Janet Dancey, et al.
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
New targets for cancer chemotherapyAnthony J Murgo, Janet Dancey, S Gail Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Lori E Dodd, Edward L Korn, Boris Freidlin, et al.
Gynecologic Oncology|August 14, 2013
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancerRachel A Goodwin, Rahima Jamal, Dongsheng Tu, et al.
Cancer|July 12, 2007
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinomaMelanie B Thomas, Romil Chadha, Katrina Glover, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2024
Correlative Science in the Cooperative Group System: Re-Engineering for SuccessPeter J O'Dwyer, Norman Wolmark, Douglas S Hawkins, et al.
Cancer Biology & Therapy|June 9, 2006
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancerAthanassios Argiris, Ezra Cohen, Theodore Karrison, et al.
Pageof 8